In recent years, selective serotonin reuptake inhibitors (SSRIs) have been the first line of medications used to treat moderate to severe anxiety disorders and depressive disorders; the mechanism of action involves blocking 5-HT, down-regulating presynaptic reuptake channels, thereby increasing synaptic concentrations of 5-HT. This evidence concerns the gene HTR5A and depressive disorder.